Desai M Y, De la Peña-Almaguer E, Mannting F
Division of Nuclear Cardiology and Nuclear Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Cardiology. 2001;95(3):156-60. doi: 10.1159/000047363.
To determine whether the use of inhaled beta-agonists decreases the duration of dobutamine stress testing (DAS), reduces the amount of dobutamine infused and decreases the use of atropine.
34 patients on beta-agonists (group A) (mean age 65 +/- 8 years) and 32 patients not on beta-agonists or beta-blockers (group B) (mean age 65 +/- 10 years) undergoing DAS with SPECT were enrolled.
The time of infusion of dobutamine in group A was 6.41 +/- 1.58 min and in group B was 9.77 +/- 3.60 min (p < 0.001). The amount of dobutamine infused was 10.64 +/- 5 mg in group A and 19.20 +/- 8 mg in group B (p < 0.001). In group A, 2 of 34 patients and 18 of 32 patients in group B needed atropine to reach peak HR (p < 0.001).
Patients on short acting beta-agonists require smaller amounts of dobutamine with a shorter infusion time during DAS, and lesser use of side-effect prone atropine.
确定吸入性β受体激动剂的使用是否会缩短多巴酚丁胺负荷试验（DAS）的持续时间、减少多巴酚丁胺的输注量并减少阿托品的使用。
纳入34例使用β受体激动剂的患者（A组）（平均年龄65±8岁）和32例未使用β受体激动剂或β受体阻滞剂的患者（B组）（平均年龄65±10岁），他们均接受了单光子发射计算机断层扫描（SPECT）的DAS。
A组多巴酚丁胺的输注时间为6.41±1.58分钟，B组为9.77±3.60分钟（p<0.001）。A组多巴酚丁胺的输注量为10.64±5毫克，B组为19.20±8毫克（p<0.001）。A组34例患者中有2例，B组32例患者中有18例需要阿托品来达到心率峰值（p<0.001）。
使用短效β受体激动剂的患者在DAS期间需要的多巴酚丁胺量较少，输注时间较短，且较少使用易产生副作用的阿托品。
